Mental healthcare company focusing on advancing innovative treatments and safe, psychedelic-assisted therapies for mental illnesses Numinus Wellness Inc. (CVE: NUMI) has integrated its psychedelic research facility so as to increase its research service capacity.
Numinus says that it has added an extra psychedelic lab and submitted an application for licensing. The company says this initiative is in line with its wider goal of expanding its services to support industry research and production as it multiplies its revenue streams.
The newly launched psychedelic lab is located in an existing building leased by the company which is adjacent to the current psychedelic lab. The new lab will be double the size of the company’s research footprint and its construction will be complete by summer 2022.
The new lab will be focusing on bio-analytical testing, small batch manufacturing, bio-essay and in-vitro studies and research, development and formulation studies for various psychedelic compounds.
“As the psychedelics industry grows, supply of clinical-grade materials and access to qualified research facilities and talent are increasingly becoming bottlenecks. Numinus Bioscience addresses this need by offering services and partnership opportunities that leverage our federal license, expertise and state-of-the-art facility,” said the company’s general manager, Sharan Sidhu.
